Fujifilm Diosynth’s Holly Springs expansion doubles biologics capacity.

FUJIFILM Diosynth Biotechnologies are setting a new industry benchmark with the expansion of its Holly Springs campus—an initiative designed to boost capacity, streamline process efficiency, and support the manufacture of complex biologics and gene therapies.

Key Details for Pharma Manufacturers:
🔹Strategic Expansion & Timeline: Launched in 2021 and on track for completion in 2025, this expansion is a pivotal element of Fujifilm Diosynth’s global CDMO ecosystem strategy, ensuring scalable production to meet evolving market needs.
🔹Enhanced Capacity & Flexibility: With investments that have effectively doubled its biomanufacturing capacity, the Holly Springs facility is engineered for enhanced throughput and operational flexibility—critical for managing fluctuating demand and complex product portfolios.
🔹Advanced Process Technologies: The facility incorporates state-of-the-art manufacturing and quality control systems. Its cutting-edge process technologies not only optimize production efficiency but also maintain the high regulatory standards essential in pharma manufacturing.
🔹Integrated Operations & Local Impact: This expansion strengthens the end-to-end production platform, facilitating seamless integration from development to manufacturing. Additionally, it serves as an economic engine in Holly Springs, driving job creation and bolstering the local biotech ecosystem.

At PlantQuest, we recognize the importance of operational excellence and innovation in pharma manufacturing. Fujifilm Diosynth Biotechnologies’ commitment to technological advancement and scalable production is a prime example of industry leadership that meets the rigorous demands of modern biopharmaceutical production.